FGF2 and pulmonary arterial hypertension: As FGF2 overproduction has been noted in the human vascular endothelium in idiopathic PAH, it is possible that fibroblast growth factors might represent potential targets for disease management [150]; however, dovitinib, infigratinib, or nintedanib treatment did not appear to substantially reverse PH manifestations.